LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

Inicio・Lista de Acciones・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Cerrado

Sector Salud

7.9 -0.25

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.88

Máximo

8.01

Métricas clave
By Trading Economics
BPA	-0.172
Margen de beneficio	-66.092
Empleados	536

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+93.81 upside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	41M 990M
Apertura anterior	8.15
Cierre anterior	7.9

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

59 / 366 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

6.1 / 7.65 Soporte y Resistencia

BioCryst Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 sept 2024, 23:10 UTC

Principales Noticias

Bank of Canada Welcomes 2% Inflation, Pivoting Focus to Growth

17 sept 2024, 16:37 UTC

Ganancias

Correction to Walmart Headlines on Aug. 15

17 sept 2024, 16:21 UTC

Adquisiciones, fusiones, absorciones

Generali Agrees to Sale of Turkish Business

17 sept 2024, 16:03 UTC

Ganancias

Correction to Estee Lauder Headline on Aug. 19

17 sept 2024, 21:45 UTC

Principales Noticias

UAW Clashes With Jeep Maker Stellantis Over Promised Factory Work -- WSJ

17 sept 2024, 21:20 UTC

Principales Noticias

Fed's 'Reverse Repo' Balance Fell to Lowest in Over 3 Years. Why It Matters. -- Barrons.com

17 sept 2024, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

17 sept 2024, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 sept 2024, 20:38 UTC

Principales Noticias

The Stock Market Is Priced for Middling Returns No Matter What the Fed Does -- Barrons.com

17 sept 2024, 20:24 UTC

Principales Noticias

U.S. Stocks Pare Gains; Traders Betting on Big Fed Cut -- WSJ

17 sept 2024, 20:05 UTC

Principales Noticias

Meta Extends Ray-Ban Partnership; Zuckerberg Says Glasses 'Next Major Tech Platform' -- IBD

17 sept 2024, 20:00 UTC

Principales Noticias

JPMorgan in Talks With Apple to Take Over Credit Card From Goldman -- 2nd Update

17 sept 2024, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

17 sept 2024, 19:28 UTC

Principales Noticias

U.S. Stocks Give Up Gains; Traders Still Betting on Big Fed Cut -- WSJ

17 sept 2024, 19:10 UTC

Principales Noticias

Forget the Fed. This is the Stock Market's Biggest Risk. -- Barrons.com

17 sept 2024, 19:08 UTC

Charlas de Mercado

Oil Futures Rise on Renewed Middle East Tensions -- Market Talk

17 sept 2024, 18:21 UTC

Charlas de Mercado

Gold Down As Investors Await Fed Decision -- Market Talk

17 sept 2024, 18:06 UTC

Charlas de Mercado

Barrick CEO Argues Valuation Case as Company Targets Growth -- Market Talk

17 sept 2024, 17:36 UTC

Charlas de Mercado

Steel Industry Challenges on Display Amid Warning from Nucor -- Market Talk

17 sept 2024, 17:32 UTC

Charlas de Mercado

Oil Futures Press Higher On Lebanon, Fed Watch -- Market Talk

17 sept 2024, 17:07 UTC

Charlas de Mercado

Canada Housing Construction To Remain Weak Through 2024 -- Market Talk

17 sept 2024, 17:04 UTC

Adquisiciones, fusiones, absorciones

Workday Is Buying Evisort in Move Into AI-Based Document Intelligence -- Barrons.com

17 sept 2024, 17:03 UTC

Principales Noticias

JPMorgan in Talks With Apple to Take Over Credit Card From Goldman -- Update

17 sept 2024, 16:43 UTC

Charlas de Mercado

Treasury Yields Rise As U.S. Indicators Show Strength -- Market Talk

17 sept 2024, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

17 sept 2024, 16:11 UTC

Principales Noticias

JPMorgan in Talks With Apple to Take Over Credit Card From Goldman -- WSJ

17 sept 2024, 16:04 UTC

Principales Noticias

U.S. Stock Indexes Rise; Traders Still Betting on Big Fed Cut -- WSJ

17 sept 2024, 15:57 UTC

Charlas de Mercado

Bank of Canada 'Completely Behind the Curve' -- Market Talk

17 sept 2024, 15:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2024, 15:50 UTC

Charlas de Mercado

Hitting 2% Inflation Not Enough to Justify Faster, Deeper Canada Rate Cuts -- Market Talk

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

93.81% repunte

Estimación a 12 meses

Media 15.33 USD 93.81%

Máximo 30 USD

Mínimo 7 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

6.1 / 7.65Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Sentimiento

By Acuity

59 / 366 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.